Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
Front Oncol 2020 Sep 01;10(xx)1321, X Zhou, W Hou, L Gao, L Shui, C Yi, H ZhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.